Core Insights - Medtronic's CFO Thierry Piéton will participate in investor conferences on March 10 and March 11, 2026, showcasing the company's commitment to engaging with investors and stakeholders [1] Company Overview - Medtronic plc, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [1] - The company employs over 95,000 people across more than 150 countries and offers technologies that treat 70 health conditions, including cardiac devices, surgical robotics, and patient monitoring systems [1] Upcoming Events - Thierry Piéton will speak at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 10:30 a.m. EST and at the Leerink Partners Global Healthcare Conference on March 11, 2026, at 9:20 a.m. EST [1] - Live webcasts of these sessions will be available on Medtronic's investor relations website [1]

Core Insights - Medtronic plc (MDT) has launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, integrating data from the InPen smart insulin pen into a single mobile app for diabetes management [1][3] Company Developments - Medtronic's Diabetes business is set to be separated and operate as MiniMed, with an IPO planned for December 2025, aiming for completion by the end of 2026 [2] - The MiniMed Go system is approved for individuals aged seven and older with insulin-requiring diabetes, and for children aged two to six under adult supervision, with a gradual rollout starting this month [4] Product Features - The MiniMed Go Smart MDI system offers real-time insights, actionable dose alerts, and a built-in advanced dose calculator, designed to assist users managing diabetes with multiple daily injections [3] - Compatibility of the Instinct Go sensor by Abbott with MiniMed Go is pending CE mark approval, allowing users to choose between a seven-day or 15-day sensor [5] Industry Outlook - The global diabetes devices market is projected to reach $35.26 billion by 2025, with a CAGR of 7.7% through 2034, driven by increasing diabetes prevalence, obesity, and advancements in monitoring technology [7] Competitive Landscape - Insulet's Omnipod 5 Automated Insulin Delivery System has expanded into the Middle East, addressing high unmet needs in the region [8] - Abbott's FreeStyle Libre has established a leading position in the CGM market, while Tandem Diabetes Care reported over $1 billion in sales and is preparing for multiple product launches [10][11]